PolyPid, which is developing a novel platform that enables the extended release of drugs to prevent infection, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The company originally filed in October 2014 to raise $20 million in an IPO led by Aegis Capital, but subsequently withdrew its offering in May 2015.
The Petach Tikva, Israel-based company was founded in 2008 and booked plans to list on the Nasdaq under the symbol POLY. PolyPid filed confidentially on November 9, 2017. Goldman Sachs, Cowen & Company and Cantor Fitzgerald are the joint bookrunners on the deal. No pricing terms were disclosed.
